Future Market Insights indicates that cardiometabolic sleep comorbidity care is shifting toward coordinated platforms that align sleep apnea therapy, diabetes medication optimization, and hypertension control within unified patient pathways. This transition is repositioning sleep disorder management within cardiometabolic programs, where sleep-disordered breathing treatment supports obesity, diabetes, and heart failure outcomes.